Lung Cancer Survivors Push Congress for $60M to Fund Life-Saving Research Breakthroughs

The real ask on Capitol Hill isn't just about numbers on a budget sheet. It's about the lives that hang in the balance, and the stories of three survivors who are walking into Congress to make that personal cost impossible to ignore.

Miriam Patterson's journey began on her 22nd birthday, not with a diagnosis, but with a hospital room filled with grief. That day, her mother was diagnosed with stage IV lung cancer. She was only 51 years old and had quit smoking a decade before. Miriam watched her mother endure chemotherapy and radiation, passing 17 months later. When my mother was diagnosed in the 1980s, there was no lung cancer screening. No immunotherapy or genetic testing. Patterson carries that silence as a promise. Years later, after a routine scan, she was diagnosed with her own cancer. The research program she joined, funded by the NIH, gave her access to a minimally invasive surgery that saved her life. Her mother's death and her own survival form a stark before-and-after. The question for Congress is clear: why was the research that could have helped her mother not available then, and why is it still not funded at the scale needed to save more lives now?

Then there's George Flower, whose story is a direct lesson in the power of a simple scan. In 2016, recovering from a heart attack, his doctor urged him to get a low-dose CT scan. I almost said, 'no.' Then I thought, 'what could it hurt?' That decision changed everything. The scan found a tumor, and he was diagnosed with early-stage cancer. If I had waited a few more years, the tumor might have grown and not have been removable. He underwent surgery and has been cancer-free for a decade. He will get to meet his first great-grandchild this summer. His advocacy is a plea to fund the screening that saved him, because the alternative is a life cut short. The funding ask is about making that "what could it hurt?" option available to everyone, not just those who remember to ask.

Finally, there's Nancy Vandespool, whose story defies the old stereotypes. Diagnosed at 38, she had never smoked. The shock of the diagnosis was overwhelming, but she fought through treatment and has been in remission since 2017. For nearly two decades, she has been an advocate, fueled by the time research has given her with her family. Research has given me more time with my family and friends-time to watch my grandson/grandchildren grow. Her two-decade journey from patient to activist shows the long-term impact of sustained investment. The core question is why funding for research into non-smokers' risks-like genetics and environmental factors-remains inadequate, leaving people like her vulnerable and fighting for answers.

Together, these stories paint a picture of a disease that strikes without warning, cuts lives short, and demands a response. The human cost is undeniable. The funding ask is the practical step to ensure that future generations don't have to repeat these painful journeys.

The $60 Million Smell Test: What It Actually Buys

Let's kick the tires on that $60 million ask. The numbers are stark. In 2021, the program was forced to reject 82 out of 119 research proposals rated excellent or outstanding simply because there wasn't enough cash. That $60 million could have funded all of those high-quality, rejected ideas. That's the tangible outcome: turning a pile of promising research plans into actual lab work and clinical trials.

Now, contrast that with the program's current reality. For the current fiscal year, Congress has already appropriated $20 million for the Lung Cancer Research Program. That's a start, but it's a tiny fraction of the broader fight. The National Cancer Institute alone is requesting over $11.5 billion for next year. The DOD program's ask is a single, focused line item in a much larger budget.

Put the $60 million in the grandest context. It's a small part of the $51.3 billion total ask for NIH and CDC cancer programs. That's the scale of the overall need. The question isn't just about this one program, but about the entire ecosystem of cancer research funding.

So, does this money buy real progress? The evidence says yes, but only if it's the first domino. Funding those 82 rejected proposals would directly advance novel technologies and treatments. It would give a lifeline to veterans, who are at significantly greater risk. But it's also a reminder that this is a drop in the bucket for the national effort. The real progress requires sustained, multi-billion dollar investments across all agencies. This $60 million is a targeted fix for a specific, solvable problem. It's a smart, efficient use of capital that could save lives.

The Real-World Utility: From Money to Lives Saved

The recent win for early detection is a policy victory, but it's only the first step. Last week, Congress passed the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act, which will soon ensure Medicare covers blood tests for multiple cancers. That's a critical move, but the real-world utility of any screening policy depends entirely on getting those tests into clinics and into the hands of patients. A law on paper doesn't fill a doctor's office.

The gap between proven benefit and actual practice is stark. Annual low-dose CT scans for high-risk patients have been shown to significantly reduce lung cancer deaths. Updated guidelines now make nearly twice as many Americans eligible. Yet, to date, less than 18.2% of those eligible are screened. That's the smell test: a life-saving tool sits underutilized. The policy win for MCED tests needs the same kind of push to translate into real-world use.

This is where the core funding ask comes in. The $60 million for the Defense Department's Lung Cancer Research Program isn't about building another bureaucracy. It's about funding the research that creates the next generation of tools patients can actually use. In 2021, the program was forced to reject 82 out of 119 research proposals rated excellent or outstanding simply for lack of cash. That $60 million could have funded all of those high-quality ideas. Each one represents a potential advance in detection, treatment, or understanding of why some patients, like Miriam's mother or Nancy, are struck so hard.

The bottom line is about utility. Does this money save lives? The evidence says yes, but only if it's spent on the right research. That $60 million buys the chance to develop better screening methods, more effective drugs, and a deeper understanding of the disease. It's a targeted investment to close the gap between what we know works and what actually gets done in the clinic. For the 30,000 to 60,000 lives that could be saved annually with wider screening, that's the kind of practical, boots-on-the-ground funding that makes a difference.